ClinicalTrials.gg
RecruitingNCT05975593METEOR-CRATRUpdated Aug 17, 2026

MicroEnvironment Tumor Effects of Radiotherapy - Comprehensive Radiobiology Assessment TRial

An interventional study of Tumor collection via biopsy and Blood collection in Locally Advanced Cervical Carcinoma, Locally Advanced Cervical Cancer and Locally Advanced Pancreas Cancer, sponsored by Washington University School of Medicine. Recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-08-17.

Sponsored by Washington University School of Medicine · Not applicable, Interventional, and Diagnostic

How we know

From the registry’s dates

  • Started Jan 2024; still recruiting 2 years 10 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
60
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 19 studies in Uterine Cervical Neoplasms by Washington University School of Medicine — 4 open to participants now, 4 under way, none of them phase 3. Uterine Cervical Neoplasms · Washington University School of Medicine.

Planned enrollment
3rd of 18
60 · median 26
Started
2024
with 2 others
No phase
10 of 19
2 open now
Registered
15th of 19
by date

Among the 19 studies in Uterine Cervical Neoplasms by Washington University School of Medicine, this one is the 3rd largest by planned enrollment of the 18 interventional ones that give a count, is one of 3 that started in 2024, is one of 10 with no phase, and was the 15th registered.

Uterine Cervical Neoplasms

2,369 studies on the registry are indexed under Uterine Cervical Neoplasms; 678 are open to participants now.

Browse Uterine Cervical Neoplasms studies →

Open to participants now

4 of the 19 studies in Uterine Cervical Neoplasms by Washington University School of Medicine are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

Where they have run

Who these studies take

Of the 476 Uterine Cervical Neoplasms studies recruiting now, 245 (51%) set no upper age limit and 191 (40%) stop at 75 or younger; 20 take children under 18; 68 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 19 studies in Uterine Cervical Neoplasms by Washington University School of Medicine, or all of them as a file.
02

Study summary

This study is a dynamically adjustable prospective longitudinal study designed to capture biospecimen (biopsy, blood, surgical) and multimodal treatment-related data (imaging, dosimetry, clinical) before, during, and after treatment with definitive-intent chemoradiotherapy for patients with locally advanced cervical and pancreatic cancer.

03

Conditions studied

  • Locally Advanced Cervical Carcinoma
  • Locally Advanced Cervical Cancer
  • Locally Advanced Pancreas Cancer
  • Locally Advanced Pancreatic Carcinoma
  • Locally Advanced Pancreatic Cancer
  • Cervical Cancer
  • Pancreas Cancer
  • Pancreatic Cancer
  • Cancer of the Cervix
  • Cancer of the Pancreas

Keywords

  • Radiotherapy
  • Chemotherapy
  • Cervical cancer
  • Pancreatic cancer
  • Biospecimen
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Confirmation of intent to receive radiotherapy for one of the following diagnoses:

    • Cervical cancer
    • Pancreatic cancer
  • performance status ≤ 2
  • At least 18 years old
  • Able to understand and willing to sign an IRB-approved written document

Exclusion criteria

Exclusion Criteria:

  • Any issue (medical, anatomic, other) that might preclude safe acquisition of biospecimens at the discretion of the treating physician
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Diagnostic
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
60 participants (estimated)

Study arms

  • Other
    Cervical Cancer

    * Patients will have blood and tumor collected at various time points throughout participation in the study. * Patients will have standard of care imaging obtained at various time points and a diffusion basis spectrum imaging (DBSI) MRI will be obtained at the end of standard of care MRI.

    Other: Tumor collection via biopsy · Other: Blood collection · Device: Diffusion basis spectrum imaging (DBSI) magnetic resonance imaging (MRI)

  • Other
    Pancreatic Cancer

    * Patients will have blood and tumor collected at various time points throughout participation in the study. * Patients will have standard of care imaging obtained at various time points and a diffusion basis spectrum imaging (DBSI) MRI will be obtained at the end of standard of care MRI.

    Other: Tumor collection via biopsy · Other: Blood collection · Device: Diffusion basis spectrum imaging (DBSI) magnetic resonance imaging (MRI)

Interventions

  • OtherTumor collection via biopsy

    Cervical cancer: Pre-radiation therapy, 1 week after beginning radiation therapy, 3 weeks after beginning radiation therapy, and recurrence. Pancreatic cancer: pre-stereotactic body radiotherapy, 12 weeks after completion of radiotherapy, and recurrence.

  • OtherBlood collection

    Cervical cancer: pre-radiation therapy, 1 week after beginning radiation therapy, 3 weeks after beginning radiation therapy, 6 weeks after completing radiation therapy, 12 weeks after completing radiation therapy, and recurrence. Pancreatic cancer: pre-stereotactic body radiotherapy, 6 weeks after completion of radiotherapy, 12 weeks after completion of radiotherapy, surgery (if applicable), and recurrence

  • DeviceDiffusion basis spectrum imaging (DBSI) magnetic resonance imaging (MRI)

    Cervical cancer: initial staging, 12 weeks after completing radiation therapy, and recurrence. Pancreatic cancer: initial staging, stereotactic body radiotherapy (SBRT) simulation, 12 weeks after completing radiation therapy, and recurrence. The imaging will be performed when possible.

    Also known as: DBSI MRI

06

What researchers measure

Primary outcomes

  1. Changes in tumor microenvironment

    Generalized linear mixed effects models will be first used to capture the changes in the longitudinal values of a single assay output over time for a given biospecimen. Random effects will be used to describe the correlation of repeated measures on the same subject over time.

    Time frame: From start of follow-up through completion of follow-up (estimated to be 5 years)

07

Study locations

1 of 1 sites recruiting
  • Washington University School of Medicine
    St Louis, Missouri 63110, United States
    Recruiting
    • Michael Waters, M.D., Ph.D. · Contactm.r.waters@wustl.edu · 314-273-0275
    • Michael Waters, M.D., Ph.D. · Principal investigator
    • Carl DeSelm, M.D., Ph.D. · Sub investigator
    • Stephanie Markovina, M.D., Ph.D. · Sub investigator
    • Julie Schwarz, M.D., Ph.D. · Sub investigator
    • Jessika Contreras, M.D. · Sub investigator
    • Dineo Khabele, M.D. · Sub investigator
    • David DeNardo, Ph.D. · Sub investigator
    • Hyun Kim, M.D. · Sub investigator
    • Kian-Huat Lim, M.D. · Sub investigator
    • Hua Li, Ph.D. · Sub investigator
    • Albert Lai, Ph.D. · Sub investigator
    • Philip Payne, Ph.D. · Sub investigator
    • Doug Caruthers, M.S. · Sub investigator
    • Esther Lu, Ph.D. · Sub investigator
    • Lei Liu, Ph.D. · Sub investigator
    • Andrea Hagemann, M.D. · Sub investigator
    • Lindsay Kuroki, M.D. · Sub investigator
    • Leslie Stuart Massad, M.D. · Sub investigator
    • Carolyn McCourt, M.D. · Sub investigator
    • Maggie Mullen, M.D. · Sub investigator
    • Matthew Powell, M.D. · Sub investigator
    • Brooke Sanders, M.D. · Sub investigator
    • Premal Thaker, M.D. · Sub investigator
08

References and documents

Individual participant data

Plan to share: Yes — Data will be presented at scientific meetings \& published in journals. Individual-level \& aggregate genomic data will be deposited/made available through GEO \& SRA. Includes sequence, transcriptomic, epigenomic, \& gene expression data. Raw mass spectra \& unprocessed proteomic data will be shared through publisher mechanisms. Will use PRIDE \& ProteomeEXchange to share protein identifications \& spectral evidence. METEOR-BLST will collaborate with ROBIN centers to share expertise, data reporting and discovering of radiation biology. Data generated in this proposal will be shared with the scientific community subject to NIH \& institutional regulations. BLST will manage \& assist in dissemination of omics data generated. NIMS data will be deposited at MetaboLights. CODEX-based imaging data will be as supplemental files within manuscripts. Processed data will be available through CIELO. Model organisms generated will be distributed freely, or deposited into a repository/stock center.

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

Time frame: Starting with the acceptance date of initial publication.

Access criteria: Scientific progress and publications will be posted on the METEOR website. The respective departments of the PIs and co-Is also maintain web sites where information and links on the investigators' work are posted. The PIs and co-Is additionally have lab web sites where summaries of the scientific progress on projects and research interests are posted.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jan 2024 (actual). Primary completion is estimated for Dec 2032, 107 months after the start.

Of 446 non-industry interventional studies with no phase under Uterine Cervical Neoplasms, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 71. This study's planned 107 months is above that.

Counting every sponsor, half of 462 studies reached it within 33 months; a quarter within 15 and three quarters within 71.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 24, 2023
First posted
Aug 4, 2023
StartActual
Jan 11, 2024
Primary completionEst.
Dec 31, 2032
CompletionEst.
Dec 31, 2032
Last update
Aug 17, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 17, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05975593
Collaborators
National Cancer Institute (NCI), The Foundation for Barnes-Jewish Hospital
Responsible party
Sponsor
First posted
Aug 4, 2023
Start date
Jan 11, 2024
Primary completion
Dec 31, 2032 (estimated)
Completion
Dec 31, 2032 (estimated)
Last update
Aug 17, 2026

Study contacts

Michael Waters, M.D., Ph.D.
Contact
m.r.waters@wustl.edu
314-273-0275
Michael Waters, M.D., Ph.D.
principal investigator · Washington University School of Medicine

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion